This 1994 review analyzed 20 English-language studies from 1967 to March 1993, focusing on the impact of pharmacologic therapy lasting ≥6 months on weight loss and maintenance. Agents studied included phentermine, mazindol, fenfluramine, dexfenfluramine, and fluoxetine. While initial weight loss varied across studies, a plateau or weight regain was commonly
This 2000 prospective surveillance study assessed the association between anorexigen use and pulmonary hypertension (PH) across 12 North American referral centers. Among 579 patients, 205 had primary pulmonary hypertension (PPH) and 374 had secondary PH (SPH). The study found a significant association between fenfluramine use and PPH, with an adjusted
This review examines various plant-derived supplements and chemical compounds with potential appetite-suppressing effects for obesity management. Notable botanicals include Caralluma fimbriata, Phaseolus vulgaris (white kidney bean), Hoodia gordonii, Gymnema sylvestre, and Garcinia cambogia. These agents are believed to influence appetite through mechanisms such as enhancing satiety, inhibiting carbohydrate absorption, and
This 1997 editorial by M. Deitel discusses findings from a multicenter case-control study involving 95 patients with primary pulmonary hypertension (PPH) and 355 matched controls. The study identified a significant association between the use of anorexic agents, particularly fenfluramine derivatives, and the development of PPH. The risk increased with longer
